Article Text

Download PDFPDF
Randomised controlled trial
Artemisinin-based combination therapy (ACT) versus atovaquone-proguanil: do not choose between but, rather, combine them
  1. Eli Schwartz1,2,
  2. Tamar Lachish3
  1. 1The Chaim Sheba Medical Center, The Center for Geographic Medicine, Tel Hashomer, Israel;
  2. 2Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel;
  3. 3The Infectious Diseases Unit, Shaare-Zedek Medical Center, Jerusalem, Israel
  1. Correspondence to : Professor Eli Schwartz, The Chaim Sheba Medical Center, The Center for Geographic Medicine, Tel Hashomer 52621, Israel; elischwa{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


Artemisinin-based combination therapies (ACTs) are the treatment of choice for uncomplicated Plasmodium falciparum malaria in malaria endemic countries. ACT resistance has already been documented in the main, but not solely in Asia,1 therefore therapeutic alternatives should be investigated. As there are no new drugs at advance stages in the pipeline, current focus should be on novel combinations of existing drugs. This prospective randomised study compares the effectiveness of three antimalaria combination drugs—two well-established combination drugs (artesunate-amodiaquine (AA) and atovaquone-proguanil (AP)) and one …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.